Stopping the Spread: A New Antibody Aimed at Metastatic Prostate Cancer

Researchers Uncover a Promising New Way To Stop Prostate Cancer From Spreading

BLUF — Bottom Line Up Front

Researchers at Umeå University (Sweden), with collaborators in London and Uppsala, engineered a fully human antibody called mAbF11 that targets a receptor, TβRI, which aggressive prostate cancer cells hijack to spread. In laboratory cells and in mice, the antibody shrank tumors and blocked metastasis to lymph nodes—working about as well as docetaxel chemotherapy, but without the weight loss and toxicity that forced the chemotherapy arm of the mouse study to stop early.

Its key trick: it blocks only the cancer-promoting arm of a signaling pathway (TGF-β) while sparing the pathway’s normal, healthy functions—which may avoid the heart and blood-vessel side effects that sank earlier drugs against this target.

The essential caveat: this is preclinical work—cell cultures and mice only. No human beings have received this antibody. Safety testing and regulatory review must come before any clinical trial. Nothing here changes treatment decisions today, but it is a genuinely promising lead worth following.

01The problem: when prostate cancer learns to travel

For most men, prostate cancer is a slow-moving disease. The danger changes sharply when cancer cells leave the prostate and colonize the lymph nodes and bones. Once the disease becomes metastatic and castration-resistant—meaning it has spread and no longer responds to hormone (androgen-lowering) therapy—treatment options thin out considerably, and this stage remains the main cause of prostate-cancer death.

Across all cancers, it is not usually the original tumor that proves fatal; it is the spread. Roughly nine out of ten cancer deaths are due to metastasis. A drug that could specifically interrupt the machinery of spreading—rather than simply poisoning fast-dividing cells the way chemotherapy does—has long been a goal. That is the target this study set out to hit.

02The discovery: cutting the wire on the “spread” signal

The work centers on a cell-surface receptor called the TGF-β type I receptor (TβRI). TGF-β is a signaling molecule with a split personality: early on it helps suppress tumors, but in advanced cancer it flips and starts driving invasion and metastasis. That double role is exactly why previous attempts to block TGF-β broadly have failed—shut it all down and you cause collateral damage.

The Umeå team zeroed in on a specific bad actor. In aggressive prostate cancer cells, an enzyme (ADAM17, also called TACE) snips the TβRI receptor. That cut releases an inner fragment—the intracellular domain, or TβRI-ICD—which travels into the cell’s nucleus, partners with a protein called p300, and switches on a genetic program (called EMT) that lets cancer cells detach, invade, and metastasize. Their new antibody, mAbF11, physically shields the cut site so the enzyme can’t make the snip. No snip, no rogue fragment, no spread signal.

An engineer’s way to picture it

Think of TβRI as a control cable running into the cancer cell’s command center. A pair of scissors (the ADAM17 enzyme) cuts the cable and sends the severed tip into the nucleus, where it flips switches that tell the cell to break loose and spread. The antibody doesn’t cut power to the whole system—it just clamps a guard over the one spot where the scissors bite, so the harmful signal is never generated. The building’s legitimate wiring keeps working normally.

That selectivity was confirmed in the lab: mAbF11 stopped the harmful nuclear fragment from forming, yet it did not disturb the receptor’s normal “SMAD” signaling—the healthy housekeeping side of TGF-β that the heart, the aorta, and the immune system depend on. An older experimental drug used for comparison (galunisertib, a kinase inhibitor) shut that healthy signaling down; the antibody left it intact.

03What the experiments actually showed

The evidence was built in layers, from human data to cells to living animals:

Human relevance. In two independent groups of men with metastatic castration-resistant disease, higher levels of the TβRI gene tracked with worse survival—confirming the target matters in real patients, not just in a dish.
In cancer cells. The antibody reduced the cancer cells’ ability to invade and switched off the genes that drive spreading.
In mice. In a model where human prostate tumors grow in the mouse prostate and spread to nearby lymph nodes, mAbF11 reduced both tumor size and the number and size of metastases, and did so in a dose-dependent way (more drug, more effect).
Head-to-head with chemotherapy. The antibody matched docetaxel—today’s standard chemotherapy for this stage—at curbing tumor growth and invasion. Tellingly, the docetaxel arm had to be halted early because half the mice lost dangerous amounts of weight; the antibody caused no such toxicity, no weight loss, and no measurable harm to heart function or the aorta.
Beyond prostate cancer. The same antibody reduced lung metastases in a mouse model of aggressive triple-negative breast cancer, hinting the strategy may extend to other solid tumors.

“The new drug has been developed to prevent metastasis… we have been able to identify the mechanisms that drive cancer cell growth, invasiveness, and metastatic spread.” — Prof. Maréne Landström, who led the study

04Why this approach may be different

For more than a decade, drugs aimed at TGF-β have stumbled—none has reached routine cancer care—largely because blocking the pathway wholesale injured the heart and the proximal aorta. The appeal of mAbF11 is precision: it disables one specific, cancer-driving event (the cut that creates the rogue fragment) while preserving the pathway’s healthy roles. In the mouse experiments, that translated into strong anti-cancer activity with a notably clean safety readout. If that separation between benefit and harm holds up in humans, it would be a meaningful advantage.

⚠ Important caveats — please read this part

This is preclinical. All results are from laboratory cells and mice. No person has been treated with mAbF11. Many drugs that look excellent in mice never succeed in people.
The immune system is a blind spot here. The mice used were immune-deficient by design, so the study could not measure how the antibody interacts with the immune system—an important unknown, since TGF-β also helps tumors evade immune attack. Combining this antibody with immunotherapy is a future research question, not a present answer.
Years of steps remain. The researchers themselves stress that additional safety studies are required, and the treatment would need approval from regulators in Europe or the United States before it could reach patients.
A financial interest is disclosed. The senior author is a founder, shareholder, and board member of MetaCurUm Biotech AB, the company developing this antibody, which also helped fund the work. This is openly stated in the paper. It doesn’t invalidate the science, but it is a reason to watch for independent replication.
No trial is enrolling. As of this writing there is no announced human clinical trial. Patients cannot access this antibody, and it should not factor into current treatment choices.

05Who did the work, and what’s next

The study was led by Professor Maréne Landström at Umeå University’s Department of Medical Biosciences, with collaborators including the prostate-cancer group of Professor Johann de Bono in London and Professor Carl-Henrik Heldin in Uppsala. Antibody development drew on the SciLifeLab Drug Discovery and Development Platform and the Umeå Biotech Incubator. Funding came from a range of public and nonprofit sources—including the Knut and Alice Wallenberg Foundation, the Swedish Research Council, the Swedish Cancer Society, and the Swedish Prostate Cancer Federation—together with MetaCurUm Biotech AB.

MetaCurUm, based in Umeå, says it is developing this antibody alongside companion biomarkers (tests to identify which patients are most likely to benefit) and hopes eventually to extend the approach to other TGF-β-driven cancers such as breast, lung, kidney, and endometrial cancer. The immediate scientific next steps are formal safety (toxicology) studies and the long regulatory path toward a first-in-human trial.

The drug	mAbF11 — an affinity-matured, fully human monoclonal antibody
The target	TGF-β type I receptor (TβRI); blocks the ADAM17/TACE cut that releases the pro-metastatic TβRI-ICD fragment
Stage	Preclinical (cell lines + mouse models). No human data.
Key result	Reduced tumor growth & lymph-node metastasis; comparable to docetaxel but without observed toxicity
Published	June 17, 2026, Signal Transduction and Targeted Therapy (open access)
Developer	MetaCurUm Biotech AB (Umeå, Sweden)

06The road to human trials: why patients aren’t being enrolled yet

A fair question follows naturally from promising results: if it works this well, when can men receive it? The honest answer is that no human trial is planned in any concrete, scheduled sense, and the developer lists the program’s stage plainly as preclinical. It helps to understand that this is not a delay in the sense of a setback—it is the normal shape of drug development. A published efficacy paper sits very early in a long, mandatory sequence. Think of it as a successful bench prototype, not a flight-ready system: the gap between “it works in the model” and “we’ll put it in a person” is where most of the real work lives, and that gap exists to protect patients. Several things have to happen first.

The safety package isn’t built yet

A single mouse efficacy study does not earn regulatory permission to dose humans. Regulators in the U.S. and Europe require a defined battery of studies beforehand: formal (GLP) toxicology, usually in two species; safety pharmacology focused on the heart and blood vessels; pharmacokinetics; immunogenicity testing; and tissue cross-reactivity mapping. That last item matters here in particular—the target exists throughout the body, so researchers must show exactly where the antibody binds across human tissues. And recall the acknowledged gap from the study itself: the mice were immune-deficient, so the drug’s effects on the immune system are simply unmeasured. That question has to be closed before a first human trial, not during one.

Manufacturing is often the longest pole in the tent

Patients cannot be dosed with research-grade material. Moving from an affinity-matured laboratory clone to a pharmaceutical-grade product means developing a stable manufacturing cell line, a scalable purification process, quality-control release testing, and stability data. For an antibody, this step alone commonly takes 18 to 24 months or more and is expensive.

This particular target raises the bar

TGF-β signaling is everywhere in the body. Earlier drugs against this pathway caused heart-valve and aortic damage—which is precisely why this program’s entire premise is selectivity. That history cuts both ways: it makes the new approach attractive, but it also makes regulators cautious, and they will demand strong evidence that the selectivity holds in humans before accepting the risk. A target with a “difficult” past lengthens the safety work.

Funding and company stage are likely the real rate-limiter

MetaCurUm is a small incubator-resident spin-off, founded in 2018 and running largely on grants—its most recent award was on the order of 1 million SEK (roughly US$90,000–100,000). The IND-enabling safety studies, GMP manufacturing, and a Phase 1 oncology trial together typically run into the tens of millions of dollars. Small biotechs usually must raise a substantial financing round or partner with a larger pharmaceutical company before any of that can proceed. In practice, this financing or licensing step often governs the timeline more than the science does. Alongside it, the company is developing companion biomarker tests to select the right patients—sensible for a precision medicine, but additional work a first trial would want in hand.

Even once all of that is complete, the regulatory choreography itself—a pre-submission meeting, assembling and filing the application, the review clock, ethics approval, and activating trial sites—adds further months when everything goes smoothly. If one factor is most likely to determine when this reaches patients, it is financing: whether MetaCurUm raises a serious round or attracts a pharma partner to fund the pre-trial work. The biology has cleared an important hurdle; from here, money and manufacturing usually set the pace. Realistically, a first-in-human study is measured in years, not months.

07What this means for patients today

Practically, it means nothing changes in your care right now—and that’s the honest bottom line. What it offers is direction: a well-characterized, selective mechanism for interrupting metastasis, backed by human survival data on the target and by clean-looking mouse results. That is a stronger starting position than many early leads enjoy. For men living with advanced disease, the useful posture is cautious optimism paired with patience: this is a lead to follow over the coming years, and a good question to raise with your oncologist as the field’s understanding of TGF-β-targeted therapy continues to mature.

Verified Sources

Flodbring Larsson P, Schmidt A, Mu Y, Zang G, Song J, Gajavilli V, Tao J, Rakhimova O, Ericsson M, Aripaka K, Halin Bergström S, Yuan W, Bogdan D, Zhang AH, Welti J, Bergh A, de Bono J, Heldin C-H, Landström M. “Targeting oncogenic TβRI signaling inhibits androgen-independent prostate cancer growth and metastasis.” Signal Transduction and Targeted Therapy. 2026 Jun 17;11(1):238. doi:10.1038/s41392-026-02737-x. PMID: 42303991; PMCID: PMC13272619.
https://www.nature.com/articles/s41392-026-02737-x
Umeå University. “Study from Umeå paves the way for a new drug against metastatic prostate cancer.” News release, July 2026.
https://www.umu.se/en/news/study-from-umea-paves-the-way-for-a-new-drug-against-metastatic-prostate-cancer_12180958/
EurekAlert! (AAAS). “Study from Umeå paves the way for a new drug against metastatic prostate cancer.” News release 1135058.
https://www.eurekalert.org/news-releases/1135058
MedicalXpress. “New drug against metastatic prostate cancer made entirely from human proteins.” July 2026.
https://medicalxpress.com/news/2026-07-drug-metastatic-prostate-cancer-human.html
SciTechDaily. “Researchers Uncover a Promising New Way To Stop Prostate Cancer From Spreading.” July 2026.
https://scitechdaily.com/researchers-uncover-a-promising-new-way-to-stop-prostate-cancer-from-spreading/
Mu Y, Wallenius A, Zang G, et al. “The TβRI promotes migration and metastasis through thrombospondin 1 and ITGAV in prostate cancer cells.” Oncogene. 2024;43:3321–3334. doi:10.1038/s41388-024-03165-3. (The earlier mechanism study underpinning this work.)
https://www.nature.com/articles/s41388-024-03165-3
MetaCurUm Biotech AB (company website).
https://metacurum.se/
Umeå Biotech Incubator (UBI). “MetaCurUm Biotech AB – Novel antibody treatment for metastatic cancers.”
https://www.ubi.se/case/metacurumbiotech/

Reference 1 is the peer-reviewed primary source and the basis for all scientific claims above. References 2–5 are official releases and secondary news coverage; reference 6 is the foundational mechanism paper; references 7–8 describe the company developing the antibody. Quotations are drawn from the primary paper and the Umeå University release.

Disclaimer: This article is an educational summary prepared for members of the Informed Prostate Cancer Support Group. It is not medical advice and does not describe a treatment currently available to patients. The antibody discussed has not been tested in humans. Always discuss your individual diagnosis and treatment options with your own physician.

Search This Blog

Informed Prostate Cancer Patient Support